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a b s t r a c t
Ethnopharmacological relevance: The plant Cecropia pachystachya Trécul has been used in Brazilian folk
medicine to treat hypertension, bladder and kidney inﬂammation and renal diseases. The aim of this
study was to evaluate the potential of the aqueous fraction from the ethanolic extract of Cecropia
pachystachya (FCP) in the management of hypertension, inﬂammation and progressive renal disease in
rats submitted to 5/6 nephrectomy.
Materials and methods: Thirty male Wistar rats submitted to 5/6 nephrectomy (5/6 NE) were untreated
(NE) or treated (NEþFCP) with the FCP (0.5 g/kg/day). The treatment started 15 days after surgery, and
the rats were followed for a period of 60 days. Systolic blood pressure (SBP) and albuminuria were
evaluated from 15–60 days after the surgical procedure. Function and estructural renal changes, TGF-β
(transforming growth factor β), MCP-1 (monocyte chemoattractant protein-1) and nitric oxide (NO)
urinary excretion were analyzed. Expression and activity of the renal enzymes arginase (ARG),
angiotensin converting enzyme (ACE), and MAP kinase p-JNK expression also were analyzed.
Results: The nephrectomized rats developed progressive albuminuria and increased SBP that was less
intense in the treated group. There was a reduction in the glomerular ﬁltration rate (GFR) in the
nephrectomized rats, which was attenuated by treatment with FCP extract. The treatment with FCP also
attenuated the histological changes, reduced the expression and activity of renal arginase, the number of
macrophages (ED-1 positive cells) and the p-JNK expression in the renal cortex of the rats submitted to
5/6 NE. The urinary excretion of TGF-β was less intense in the treated group and was associated with the
reduction of the expression and activity of the renal arginase.
Conclusions: These results suggest that the reduction of renal arginase activity, p-JNK and TGF-β
expression can explain the mechanism by which the treatment with C. pachystachya reduced the
inﬂammation and improved renal function. This study presents the potential use of Cecropia
pachystachya in the treatment of chronic renal diseases.
& 2014 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
The Cecropia genus has extensive use in folk medicine. The plants
are native from South and Central America and are known as
embauba (Lorenzi and Matos, 2002). Cecropia pachystachya Trécul
is traditionally used in folk medicine to treat asthma, bronchitis
(Soraru and Bandoni, 1978) and diabetes (Lorenzi and Matos, 2002).
Ethnobotanical studies realized in Brazil have shown that Cecropia
pachystachya has been used traditionally to the treatment of the
renal diseases (Alves and Povh, 2013) and as analgesic to renal pain
(Bessa et al., 2013).
We recently also reported that Cecropia pachystachya aqueous
extract attenuated hypertension and renal lesion in rats subjected
to 5/6 nephrectomy (5/6 NE) by decreasing angiotensin converting
enzyme (ACE) activity in the renal cortex (Maquiaveli et al., 2014).
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The 5/6 NE is a model of chronic renal failure (CRF) characterized
by hypertension, proteinuria, inﬂammation, loss of renal function
and histological changes similar to those observed in many renal
human diseases (Kleinknecht et al., 1995). One of the main
features observed in this experimental model is an increase in
renin–angiotensin–aldosterone system (RAAS) activity, which
results in renal hemodynamic changes and inﬂammation (Taal
and Brenner, 2000).
Several studies have shown that an increase in RAAS activity
associated with a reduction in L-arginine availability contributes to
the loss of renal function in this model (Ashab et al., 1995;
Sabbatini et al., 2003). L-arginine is an amino acid endogenously
synthesized in renal proximal cells from L-citrulline and is then
degraded through distinct enzymatic routes that may affect renal
function and morphology (Reyes et al., 1994). In rats subjected to
5/6 NE the treatment with captopril associated with L-arginine
supplementation was more effective than the treatment only with
an ACE inhibitor (Ashab et al., 1995). The improved renal function
and renal plasmatic ﬂow (RPF) observed in these animals were
associated with a reduction of the inﬂammation induced by
angiotensin II (AII) and an increase in nitric oxide (NO) production
(Ashab et al., 1995).
Arginase is a key enzyme in the regulation of the production of
NO because this enzyme shares the L-arginine substrate with nitric
oxide synthase (NOS). The increase in arginase activity not only
reduces NO production but also increases the synthesis of proline,
a precursor amino acid of collagen production. Therefore, arginase
can contribute to an increase of the interstitial ﬁbrosis in inﬂam-
matory processes (Schnorr et al., 2008) that are observed in
chronic renal diseases. The inhibition of arginase by ﬂavanoids
present in cocoa was recently reported (Schnorr et al., 2008).
Cecropia pachystachya leaves are rich in polyphenols mainly
ﬂavonoids that can inhibit ACE (Lacaille-Dubois and Wagner, 2001)
and arginase in vitro. Therefore, the objective of the present study
was to evaluate the effect of the aqueous fraction from ethanolic
extract of Cecropia pachystachya (FCP) on hypertension, inﬂamma-
tion, arginase and ACE activity in model experimental of renal
disease.
2. Materials and methods
2.1. Plant material, preparation and administration of the FCP
Cecropia pachystachya Trécul (URTICACEAE) was collected at
Ribeirão Preto (-21.167925, -47.859927, altitude 546 m), state of
São Paulo, Brazil. A voucher specimen (ESA 120140) from the plant
was identiﬁed by MSc. Gerson Oliveira Romão and deposited in
the Herbarium of the ESALQ, University of São Paulo. The dried
leaves of Cecropia pachystachyawere ground in a mill (type Wyllie,
Tecnal, Piracicaba, São Paulo, Brazil) to obtain a powder, which was
used to prepare ethanolic extract. A Soxhlet system was used in
hot and standard extraction to extract lipids from Cecropia
pachystachya powdered leaves using hexane as a solvent. After
lipid extraction, ethanolic extract (EE) was prepared by a macera-
tion process at 2% w/v (weight of powdered leaves/volume of
ethanol). The maceration process was performed for 72 h at room
temperature. After extraction, the EE was ﬁltered and the solvent
was removed by rotary evaporation under reduced pressure
(100 mmHg) at 55 1C. After this, the water soluble fraction of
the EE (FCP) was obtained by adding 500 mL of distillate water at
42 1C to the resulting EE dry extract from 4 L. The samples were
centrifuged at 4500g and supernatant (FCP) was frozen at 20 1C
until its administration. Samples in triplicate of 25 mL of each
bottle were lyophilized to verify the concentration of FCP. Based on
an evaluation of water consumption of the animals over a 24 h
period, the FCP was defrosted and diluted for administration to
achieve a minimum dose of 0.5 g/kg/day. The dose of FCP was
determined from a previously pilot experiment based on the effect
in systolic blood pressure (SBP) after 15 days of treatment
(Maquiaveli et al., 2014). The FCP was administered in amber glass
drinkers given daily to the animals. The consumed volume of the
FCP per cage was determined, and the mean dose was evaluated
during the treatment.
2.2. Characterization of the active constituents from C. pachystachya
The proﬁle of the constituents from Cecropia pachysatachya FCP
extract was performed using liquid chromatography–mass spectra
(LC–MS) using Esquire 3000 Plus (Bruker Daltonics) as described
previously (Cruz et al., 2013).
2.3. Animals and experimental protocols
Thirty male Wistar rats (180–200 g) were utilized in this study.
The animals were maintained 3 rats per cage at a temperature of
22 1C with a light–dark cycle of 12 h and fed with standard diet ad
libitum. The experiments were performed in accordance with the
ethical principles for animal experimentation adopted by the
Brazilian College of Animal Experimentation, and the Animal
Experimentation Committee of the University of São Paulo at
Ribeirão Preto School of Medicine approved the study protocol
(COBEA/CETEA/FMRP-USP, Protocol no. 050/2010). The animals
were subjected to 5/6 NE according to the technique described
previously (Chanutin and Ferris, 1932). The animals were anesthe-
tized with ketamine (90 mg/kg) and xylazine (10 mg/kg) per
intramuscular injection. The right kidney was removed, and an
infarction was provoked in two-thirds of the left kidney by ligation
of two branches of the left renal artery. In the control group, a
sham (S) operation was performed by laparotomy and manipula-
tion of the renal pedicles without causing ischemia or destruction
of renal tissue. The animals were divided into 3 groups (n¼10 per
group): untreated animals that were subjected to sham surgery(S);
untreated animals that were subject to 5/6 nephrectomy (NE); and
animals treated with FCP that were subjected to 5/6 NE (NEþFCP).
The treatment with FCP started 15 days after surgery. After the
surgical procedure, all groups were followed for a period of 60
days. Body weight (BW) and systolic blood pressure (SBP) mea-
sured by the tail-cuff method (CODA System, Kent Scientiﬁc,
Torrington, Connecticut, USA) were evaluated from 15–60 days
after surgery. The animals were placed in metabolic cages for 24 h,
and urine samples were collected to quantify albumin excretion
(AE) and NO production.
2.4. Renal function studies
The albumin in urine samples was quantiﬁed by electroimmu-
noassay and the glomerular ﬁltration rate (GFR) was evaluated 60
days after surgery by inulin clearance. The rats were anesthetized
with sodium thiopental (40 mg/kg, intraperitoneally). After tra-
cheostomy, the femoral artery and vein were cannulated to collect
blood samples and to inject ﬂuids, respectively. The ureters were
cannulated to collect urine. Urine samples were collected before
the administration of inulin solution to analyze TGF-β and MCP-1.
After urine sample collection, the rats received a priming inulin
dose (12 mg/100 g diluted in PBS solution, pH¼7.4), followed by a
maintenance inulin dose of 0.5 mg/min/100 g. After 60 min of
stabilization, urine was collected for 1 h, and the blood was
sampled at 30 and 60 min. The kidneys were perfused through
the aorta with PBS solution and removed for histological and
immunohistochemical studies. The animals were euthanized via
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anesthesia overdose. Inulin was quantiﬁed in the plasma and urine
samples by the method described by Fuhr et al., 1955.
2.5. Quantiﬁcation of TGF-β and MCP-1 in urine
The urine samples collected by the ureter were immediately
treated with 1 mM phenylmethylsulfonil ﬂuoride (PMSF, Sigma
Chemical Co, St. Louis, Missouri, USA) and stored at 70 1C until
analysis. The TGF-β and MCP-1 quantiﬁcation was performed by
enzyme immunoassay (ELISA) using commercial kits (Promega
Corporation, Madison, Missouri, USA and Pierce, Rockford, USA,
respectively). The median values of TGF-β and MCP-1 were
expressed in pg of TGF-β or MCP-1 per mg creatinine.
2.6. Determination of urinary NO levels
The samples of urine collected in 24 h from control and
nephrectomized groups were aliquoted and deproteinized with
95% ethanol (4 1C) 1:2 (lysate:ethanol) and centrifuged at 4000g
for 5 min. The supernatant was utilized to determine NO content
by the NO/Ozone technique described previously (Hampl et al.,
1996) using a Sievers analyzer (Sievers 280 NOA, Sievers, Boulder,
CO, USA).
2.7. Light microscopy
Histological sections (3 mM) were stained with Masson's tri-
chrome and analyzed by a light microscope. The incidence of
segmental glomerulosclerosis was determined by scoring 50
glomeruli in a section of each kidney. The scores reﬂected changes
in the extension of the lesion (0¼0–5%, 1¼5–25%, 2¼25–50%,
3¼50–75%, and 4¼475%). Tubulointerstitial injury in the cortical
area was deﬁned as inﬂammatory cell inﬁltrates, tubular dilation
and/or atrophy or interstitial ﬁbrosis. Injury was graded on a scale
of 0–4: 0¼normal, 0.5¼focal and discrete changes, 1¼changes
involving less than 10% of the renal cortex, 2¼ involvement of 10–
25% of cortex, 3¼ involvement of 25–75% of cortex and
4¼extensive damage involving more than 75% of the renal cortex.
2.8. Immunhistochemical analysis
The sections were incubated at 4 1C overnight with 1/30 anti p-
JNK monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz,
California, USA), 1/200 anti-AII polyclonal antibody (Peninsula
Laboratories, San Carlos, USA) or 1/500 anti-Arginase I polyclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or for
1 h with 1/1000 anti-ED1 monoclonal antibody that only reacts
with cytoplasmic antigen present in macrophages and monocytes
(Serotec, Oxford, UK) and 1/500 anti-vimentin monoclonal anti-
body (Dako, Glostrup, Denmark). The reaction product was
detected with an avidin–biotin–peroxidase complex (Vector
Laboratories, Burlingame, California, USA). Negative controls were
created by replacing the primary antibody with normal mouse
immunoglobulin G (IgG) or rabbit IgG for monoclonal or poly-
clonal antibodies, respectively, at equivalent concentrations. The
color reaction was developed with immunoglobulin G (Sigma
Chemical Company, St. Louis, Missouri, USA). The sections were
counterstained with methyl green or with Harris hematoxylin,
dehydrated and mounted. Scores for p-JNK and Arginase I (ARG 1)
were obtained through of the analize of 50 glomeruli and 30 ﬁelds
in the tubulointerstitial area (measuring 0.200 mm2), and the
mean score per kidney was calculated. Vimentin was used as a
marker of tubular cell lesions and was assessed only in the
tubulointerstitial area (Coimbra et al., 2000). The scores mainly
reﬂected changes in the extent, rather than the intensity,
of staining and depended on the percentage of glomeruli or
grid ﬁeld showing positive staining: 0¼0–5%, 1¼5–25%,
2¼25–50%, 3¼50–75% and 4¼475%. The number of ED1 (macro-
phages/monocytes)-positive cells (glomeruli and renal cortical
tubulointerstitium) and of AII-positive cells (cortical tubulointer-
stitium) were counted through the examination of 50 glomeruli
and 30 grid ﬁelds (measuring 0.200 mm2), respectively, and the
mean counts per kidney were calculated.
2.9. Arginase inhibition assay
Rat liver arginase was prepared by blending 30 g of tissue with
300 mL of 100 mM Tris–HCl buffer (pH 7.4) containing 1 mM
PMSF. The homogenate was centrifuged at 20,000g, and the
supernatant was fully activated by incubation with 10 mM MnSO4
at 60 1C for 10 min. The extract was newly centrifuged at 20,000g
for 10 min, and the supernatant was submitted to chromatography
on a Chelating Sepharoses (GE Healthcare) column charged with
Niþ2 to remove blood pigments. The eluate was then used to test
the inhibition of arginase in vitro. Renal cortex arginase was
prepared by homogenizing 0.2 g of tissue with 500 mL of
100 mM Tris–HCl buffer (pH 7.4) containing 1 mM PMSF, centri-
fuged at 20,000g for 10 min. The supernatant was fully activated
with 10 mM MnSO4 at 60 1C for 10 min. The arginase activity was
evaluated in reactions performed in 50 mM CHES buffer (pH 9.5)
and 50 mM L-arginine (pH 9.5) and arginase enzyme in a ﬁnal
reaction volume of 100 mL. The reaction mixtures were incubated
at 37 1C for 15 min and 60 min, respectively for liver and renal
arginase samples. In the inhibition test in vitro, FCP or orientin
(Sigma-Aldrich) was added to the reaction mixture to a ﬁnal
concentration of 0.33 mg/mL. The control experiments were per-
formed under the same conditions but in the absence of the
inhibitor. All arginase assays were performed in duplicate in two
independent experiments. Arginase activity was measured by urea
production determined by the Berthelot method. The activity of
arginase in the renal cortex was determined by the amount of urea
formed in nmol/mg of protein.
2.10. ACE inhibition assay
The catalytic activity of ACE was determined by the ﬂuorimetric
method assay (Friedland and Silverstein, 1976). The renal cortex
(1 g) was homogenized with 10 mL of 100 mM borate buffer (pH
7.2) containing 340 mM sucrose, 300 mM NaCl and 100 mM PMSF.
The homogenate was centrifuged at 5000g, 4 1C for 10 min and the
supernatant was conditioned at 70 1C until analysis. An aliquot
of 10 mL plasma or renal homogenate was incubated with 200 mL of
assay solution (1 mM Z–Phe–His–Leu, 100 mM sodium borate
buffer, pH 8.3, 300 mM NaCl and 0.1 mM ZnSO4) for 10 min at
37 1C. The reaction was stopped by adding 1.5 mL of 280 mM
NaOH. Then, 100 mL of o-phtaldialdehyde at 20 mg/mL diluted in
methanol was added to the reaction, and after 10 min the reaction
was acidiﬁed with 200 ml of 3 N HCl. The mixture was centrifuged
at 3000g for 10 min at room temperate. The HL (His–Leu) peptide
released was measured by ﬂuorimetry (360 nm of excitation and
465 nm of emission) in a Tecan inﬁnity F200 system (Oliveira et al.,
2000). The median values of the renal and plasmatic ACE activity
were expressed in nmol/mg of protein and mU/mL of HL produced,
respectively. The ACE activity assay was performed in vitro repla-
cing the tissue with rabbit lung ACE (EC 3.4.15.1, Sigma-Aldrich) in
the presence of the 10 mM captopril or 0.33 mg/mL FCP. The
captopril and FCP were pre-incubated with rabbit lung ACE for
30 min at 37 1C. ACE activity in the presence of inhibitors was
expressed in mU/mL of produced HL.
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2.11. Statistical analysis
One-way analysis of variance (ANOVA) with Newman–Keuls
was applied for the data that presented normal distribution and
homogeneity of variance (SBP and arginase activity in vitro). Those
data were expressed as the means and standard errors of the mean
(SEM). For data related to other studied parameters, we used a
nonparametric Kruskall–Wallis test with Dunn's post-test. Those
data were expressed as the median values and interquartile.
Statistical analyses were performed using Graph Pad Prism version
5.0 for Windows, Graph Pad Software, San Diego, California, USA.
The level of statistical signiﬁcance was set at po0.05.
3. Results
3.1. Determination of the FCP extract dose and body weight (BW)
The daily dose of FCP consumed by the treated nephrectomized
group (NEþFCP) was 0.5070.02 g/kg. The body weight (BW) did
not differ between the groups except before treatment when the
NEþFCP rats presented lower BW when compared to the control
group S (Table 1).
3.2. Characterization of the active constituents from C. pachystachya
In an attempt to identify the major constituents of FCP, we
performed LC–MS analysis using standard ﬂavonoids (Sigma-
Aldrich). The compound orientin was identiﬁed by RT and UV/
VIS spectra that matched with the authentic sample.
3.3. Determination of the systolic blood pressure (SBP), albuminuria
(AE) and glomerular ﬁltration rate (GFR)
The untreated rats subjected to 5/6 NE (NE group) presented an
increase in the systolic blood pressure (SBP) and albuminuria (AE)
when compared to the control group S. However, there was a
signiﬁcantly reduction in the SBP in the NEþFCP group when
compared with NE group after 15 days of treatment with FCP, which
corresponds to 30 days after surgery (Table 1) (po0.05). The increase
of SBP and AEwas also attenuated by treatment with FCP 60 days after
surgery (Table 1). The glomerular ﬁltration rate (GFR) was 0.43 mL/
min/100 g (median value) in the control group and fell to 0.17 mL/min/
100 g in the untreated NE group (po0.01), representing a fall of 60.5%
in the GRF in comparison to control group. The decrease of the GFR
was less intense in the treated NEþFCP group, in which a reduction of
46.5% was observed (0.23 mL/min/100 g) (Fig. 1).
3.4. Quantiﬁcation of TGF-β, MCP-1 and NO in urine
There was an increase of the urinary rate of TGF-β in the NE group
in comparison to control group S (po0.01). This increase was also
less intense in the NEþFCP group (Table 2). The urinary excretion of
the MCP-1 and NO did not differ between groups (Table 2).
3.5. Light microscopy
The rats subjected to 5/6 NE presented morphological features
that are characteristic of this model: glomerulosclerosis, tubular
lumen dilation with ﬂattening of proximal tubular cells, tubular
atrophy and increased interstitial area with inﬂammatory cell
inﬁltrates [Fig. 2(a)–(c)]. These histological changes were less
intense in the NEþFCP group [Fig. 2(a)–(c) and (g)–(h)].
3.6. Immunohistochemical analysis
The expression of the vimentin protein in the tubulointerstitial
area was higher in the renal cortex of the rats subjected to 5/6 NE,
and this increase was attenuated by treatment with FCP [Fig. 2(d)–
(f) and (i)]. The increased p-JNK expression in the renal cortex
Table 1
Systolic blood pressure (SBP), urinary albumin excretion (AE) and body weight (BW) in rats from the control group (S) and in rats subjected to 5/6 NE, untreated (NE) or
treated (NEþFCP) with FCP 15–60 days after surgery.
Days (d) after surgery 15 d 30 d 60 d
SBP, mmHg
S 134712 12576 13174
NE 18279n 190711nn 176714n
NEþFCP 172711n 160712n,nnn 166714
AE, mg/24 h
S 0.28 (0.15; 0,72) 0.34 (0.01; 0,72) 0.51 (0,33; 0,63)
NE 59.20 (30.78; 79.84)n 104.1 (23.75; 188.8)nn 126.8 (48.75; 213.0)nn
NEþFCP 23.80 (17.80; 106.0)n 20.00 (10.20; 121.9) 60.60 (24.33; 154.5)
BW, g
S 330 (315; 335) 460 (449; 483) 516 (470; 647)
NE 300 (276; 314) 404 (359; 441) 501 (458; 552)
NEþFCP 282 (256; 405)n 393 (367; 434) 432 (408; 517)
Data are presented as means7SEM (SBP) and median values and quartiles (25; 75%) (AE and BW).
n po0.05.
nn po0.01 vs S.
nnnn po0,05 vs NE.
Fig. 1. Glomerular ﬁltration rate (GRF) of rats from control group (S) and nephrec-
tomized groups treated (NEþFCP) and untreated (NE) with FCP, 60 days after
surgery. The bars represent median values and interquartiles (25–75%). nnpo0.01.
Groups with n¼5.
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tubulointerstitium and increased ED-1 expression in the glomeruli
observed in the nephrectomized rats were also lower in the
NEþFCP rats (Fig. 3). The number of the AII positive cells in the
tubulointerstitium did not differ signiﬁcantly between the groups
(p40.05) [Fig. 4(a)–(c) and (g)]. Arginase 1 (ARG 1) expression
was more intense in the glomeruli of rats from untreated NE group
when compared with control group S (po 0.05), and the treat-
ment with FCP also attenuated the ARG 1 expression in the
glomeruli [Fig. 4(d)–(f) and (i)].
3.7. ACE and ARG activity
A tendency of increased ACE activity in the renal cortex of the
untreated NE groups was observed. However, the treatment with
FCP did not interfere with ACE activity in the renal tissue and
plasma (Table 3). The FCP fraction did not inhibit ACE activity
in vitro at the concentration of 0.33 g/mL (Fig. 5(a)), while
methanolic extracts obtained from Cecropia pachystachya leaves
at 0.33 g/mL showed 42% of ACE inhibition (Lacaille-Dubois and
Wagner, 2001). On the other hand, the arginase activity was
increased in the renal cortex in the untreated NE group when
compared to control group S (po0.01), and this increase was
prevented by treatment with FCP (Table 3). We observed also that
ARG 1 activity in vitro was inhibited in 45% by FCP fraction (Fig. 5
(b)). ARG 1 inhibition should be related to other compounds
present in FCP that were not identiﬁed because the orientin
ﬂavonoid was not able to inhibit the enzyme in vitro (Fig. 5(b)).
4. Discussion
The results of this study showed that treatment with Cecropia
pachystachya fraction (FCP) reduced hypertension and inﬂamma-
tion, as well the functional and structural renal changes in 5/6 NE
rats. Our results corroborated with those of others studies that have
shown the anti-hypertensive activity of the plants of the Cecropia
genus (Lima-Landman et al., 2007; Maquiaveli et al., 2014).
Fig. 2. Representative Masson's trichrome-stained histological sections of renal cortex (a–c) and vimentin staining (d–f) of rats from (a, d) control, (b, e) 5/6 nephrectomy
(NE) and (c, f) NEþFCP groups 60 days after surgery. Note that glomerular sclerosis, interstitial lesions and the expression of vimentin in tubule cells in (b) and (e) are more
intense than (c) and (f), respectively. Bars represent 50 mm. Score for tubulointerstitial lesion (g) and glomerular sclerosis (h), and vimentin (i) in the renal cortical
tubulointerstitium per area of renal cortex measuring 0.200 mm2 in control rats (S) and rats subjected to 5/6 NE treated (NEþFCP) or untreated (NE) with FCP 60 days after
surgery. Horizontal lines represent the median values.npo0.05, nnpo0.01 vs S. Groups with n¼5.
Table 2
Transforming growth factor β (TGF-β), monocyte chemoattractant protein-1 (MCP-1)
and nitric oxide (NO) urinary excretion in the control group (S) and rats subjected to
5/6 NE, untreated (NE) or treated (NEþFCP) with FCP 60 days after surgery.
TGF-β(pg/mg urinary
creatinine )
MCP-1(pg/mg urinary
creatinine )
NO(mmol/mg
urinary creatinine)
S 127 (66; 148) 1740 (1110; 2432) 0.94 (0.77; 1.35)
NE 4888 (2425; 5788)nn 1305 (551; 14160) 1.08 (0.71; 1.22)
NEþFCP 1946 (500; 2454) 1554 (584; 5541) 1.00 (0.44; 1.52)
Data are presented as median values and interquartiles (25; 75%).
nn po0.01 vs S.
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Albuminuria and hypertension are important risk factors for the
loss of kidney function, and reductions in both have been associated
with slower progression of the renal disease (Levey et al., 2005).
The reduction of the vimentin expression associated with the
histological studies indicated that FCP can reduce glomerular and
tubulointerstitial lesions in rats subjected to 5/6 NE. Vimentin is an
important marker of recent tubular lesion because cells only
express vimentin when they are proliferating (Coimbra et al., 2000).
Recently we showed that aqueous extract of Cecropia pachystachya
(CP extract) reduced renal inﬂammation in the rats subjected to 5/6
NE via reduction of p-JNK expression and macrophage recruitment.
These effects were associated with presence of chlorogenic acid in the
Fig. 3. Representative immunostaining in the renal cortex for (a–c) p-JNK and (d–f) ED1-positive cells (macrophages) from rats from control (a, d), NE (b, e) and NEþFCP (c,
f) groups, 60 days after surgery. Note that the expression of p-JNK in the tubular and interstitial cells and number of ED1-positive cells in glomerulus are higher in (b) and
(e) than in (c) and (f). Bars represent 50 mm. Score for p-JNK (g, h) and number of ED1-positive cells (i, j) in the renal tubulointerstitium (g, i) and glomerulus (h, j), in control
rats (S) and rats subjected to 5/6 NE treated (NEþFCP) or untreated (NE) with FCP 60 days after surgery. Horizontal lines represent median values. npo0.05, nnpo0.01 vs S.
Groups with n¼5.
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CP extract (Maquiaveli et al., 2014). In this study, we used the ethanolic
extract from Cecropia pachystachya (FCP), which did not have chloro-
genic acid. The main compound identiﬁed in FCP was the orientin
ﬂavonoid, which has been previously shown to have important anti-
inﬂammatory effects (Aragão et al., 2013; Ku et al., 2014). Ku et al.
(2014) veriﬁed that orientin attenuated vascular inﬂammation induced
by high glucose (HG) via reduction of both nuclear factor Kappa B
(NFk-B) and adhesion molecules (CAMs) expression, resulting in the
reduction of the monocyte adhesion. Therefore, the presence of
orientin FCP also could be associated with reduction of p-JNK
expression and macrophage recruitment in the renal cortex. This
result supports anti-inﬂammatory effect by the FCP. MAPK c-Jun
N-terminal Kinase (JNK) pathway has been implicated in apoptosis,
inﬂammation and synthesis of inﬂammatory mediators (Maquiaveli et
al., 2014). The use of the Cecropia pachystachya leaves by Brazilian
people in renal diseases (Alves and Povh, 2013; Bessa et al., 2013), in
part, could be explicated by reduction of the inﬂammation. The anti-
inﬂammatory effect of Cecropia pachystachya also was demonstrated
in other experimental model of inﬂammation (Aragão et al., 2013).
Macrophages and renal tubular cells producing the TGF-β
during the inﬂammatory process induced by 5/6 NE. TGF-β is
one of the major ﬁbrogenic cytokines and enhances the synthesis
of matrix components and blocks matrix degradation, thereby
promoting extracellular matrix (ECM) accumulation. Therefore,
the protective effect of the treatment with FCP in reducing
interstitial and glomerular ﬁbrosis may be related a decreased
renal production of this ﬁbrogenic cytokine. The increase of TGF-B
is related with increase of the RAAS activity in this renal failure
model. Previously, we showed that CP extract reduced ACE activity
and AII expression as well as TGF-β production, in the renal cortex
of rats subjected to 5/6 NE, 90 days after nephrectomy (Maquiaveli
et al., 2014). However, in the present study we veriﬁed that AII
expression and ACE activity did not differ between control and
nephrectomized groups, 60 days after surgical procedure. There-
fore, the treatment with FCP attenuated TGF-β production, inﬂam-
mation, and renal lesion independent of changes in the ACE
activity.
On the other hand, we veriﬁed that arginase 1 expression in the
glomerulus and renal arginase activity were decreased in the
neprectomized rats treated with FCP. ARG 1 is higher in the liver
Fig. 4. Representative immunostaining cells positive for angiotensin II (AII) in the renal cortex (a–c) and for cells positive for arginase 1 in the glomerulus (ARG 1) (d–f) of
rats from control (a, d), NE (b, e) and NEþFCP (c, f) groups 60 days after surgery. Note that the expression ARG 1 in the glomerulus is more intense in (e) than in (f). Bars
represent 50 mm. The number of cells positive AII (g) and ARG 1 in the renal tubulointerstitium (h) and glomerulus (i) in control rats (S) and rats subjected to 5/6 NE treated
(NEþFCP) or untreated (NE) with FCP 60 days after surgery. Horizontal lines represent median values. npo0.05 vs S. Groups with n¼5.
Table 3
Angiotensin converting enzyme (ACE) and renal arginase activity in the control
groups (S) and rats subjected to 5/6 NE, untreated (NE) or treated (NEþFCP) with
FCP 60 days after surgery.
Renal ACE activity
(nmol/mg of
protein)
Plasma ACE activity
(nmol/mg of protein)
Renal arginase activity
(nmol/mg of protein)
S 0.59 (0.45; 1.02) 68.25 (45.85; 101.1) 160.4 (126.7; 183.7)
NE 1.01 (0.34; 1.54) 57.20 (49.30; 89.58) 236.5 (198.0; 509.0)nn
NEþFCP 0.85 (0.34; 1.39) 79.30 (54.18; 86.90) 183.0 (136.8; 266.2)
Data are presented as median values and interquartiles (25; 75%).
The assays were performed in duplicate in two independent experiments.
nn po0.01 vs S.
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and arginase 2 (ARG 2) is more abundant in the kidney (Schnorr et al.,
2008). However, after the development of hypertension, increases the
expression of ARG 1 and ARG 2 and L-arginine transporters in afferent
arterioles are observed (Hultström et al., 2009). In inﬂammatory
diseases, ARG 1 expression increases in macrophages (Schnorr et al.,
2008). Therefore, arginase inhibition may offer an alternative target
to treat endothelial dysfunction in hypertension (Michell et al., 2011)
and renal failure (Sabbatini et al., 2003). ARG 1 expression is also
induced in cardiac disease, and its inhibition regulates blood pressure
(Bagnost et al., 2008) andmediates cardioprotection during ischemia-
reperfusion (Jung et al., 2010).
In children with progressive renal disease, a signiﬁcant increase
in the levels of assimetric dimethylarginine (ADMA) and simetric
dimethylarginine (SDMA), analogous of the L-arginine that blocks
eNOS activity by competitive inhibition, was observed (Kari et al.,
1997; Vallance et al., 1992). Plasma levels of L-arginine were also
decreased in these patients. Other molecules that accumulate in
uremia such as IL-8 also inhibit NOS (Vallance et al., 1992). Despite
the fact that urinary excretion of NO did not change in this
experiment, the reduced expression of ARG 1 in the glomerulus
may be an indication that Cecropia pachystachya components
could be interfering with the metabolism of the amino acid
L-arginine. TGF-β has been shown to increase the expression of
the arginase in macrophages (Boutard et al., 1995). The reduction
of renal arginase activity could have occurred by reduction in
expression of the arginase enzyme due to reduced production of
TGF-β. For the ﬁrst time we veriﬁed that FCP extract from Cecropia
pachystachya reduced ARG 1 expression and ARG activity in the
renal cortex of 5/6 NE rats, which may have contributed to the
reduction renal inﬂammation and ﬁbrosis. In addition we showed
for the ﬁrst time that FCP inhibited ARG 1 in vitro. The production
of L-ornithine by arginase is the ﬁrst step in the polyamine
pathway, and L-ornithine is also a substrate for proline biosynth-
esis that is involved in cell differentiation and the synthesis of
collagens (Reyes et al., 1994). Therefore, the reduction in the
activity/expression of renal arginase and the synthesis of renal
TGF-β may contribute to the reduction of the glomerular and
tubulointerstitial ﬁbrosis observed in the treated neprectomized
rats with FCP extract.
5. Conclusion
The FCP extract from Cecropia pachystachya reduced inﬂamma-
tion and renal arginase activity in rats subjected to 5/6 NE. These
results suggest that reduction of renal arginase activity, p-JNK and
TGF-β expression can explain the mechanism by which this plant
to reduce inﬂammation and renal lesion. These mechanisms not
are only associated with the reduction of the ACE activity. Cecropia
pachystachya extract can act through multiple mechanisms to
improve renal function, including decreases in ARG activity and
expression, as well as through anti-inﬂammatory effects.
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